Literature DB >> 1906073

Practice guidelines and malpractice litigation: collision or cohesion?

T A Brennan1.   

Abstract

Practice guidelines are standardized specifications for managing particular clinical problems and are intended to improve the outcomes of medical care by increasing adherence to standards of care. They are also meant to make medicine more cost-effective by eliminating unnecessary procedures. A relatively recent phenomenon, the practice guidelines now emerging will have implications for malpractice, which also intends to bring about better care. They will probably not revolutionize the procedures that courts use to determine negligence, but judges will integrate guidelines into their decision-making process. This development should be welcomed. Guidelines should prove to be useful as either inculpatory or exculpatory evidence of negligence. They are unlikely to generate much new litigation, although there is some potential for suits against those who issue guidelines, especially if guidelines are not revised as the technology of medical care changes.

Mesh:

Year:  1991        PMID: 1906073     DOI: 10.1215/03616878-16-1-67

Source DB:  PubMed          Journal:  J Health Polit Policy Law        ISSN: 0361-6878            Impact factor:   2.265


  4 in total

Review 1.  The mammography and prostate-specific antigen controversies: implications for patient-physician encounters and public policy.

Authors:  A S Brett
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

2.  Clinical practice guidelines as legal norms.

Authors:  D Jutras
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

Review 3.  Clinical practice guidelines: from methodological to practical issues.

Authors:  N Roche; P Durieux
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

Review 4.  The US Public Health Service "treating tobacco use and dependence clinical practice guidelines" as a legal standard of care.

Authors:  Randy M Torrijos; Stanton A Glantz
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.